American Vietnamese Biotech, Inc.

  • Market Cap: N/A
  • Industry: Medical Specialties
  • ISIN: VN000000AMV5
VND
1,800.00
-100 (-5.26%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

With a fall in PBT of -256.88%, the company declared Very Negative results in Mar 25

  • The company has declared negative results in Jan 70 after 2 consecutive negative quarters
  • NET SALES(Q) At VND 63,555.05 MM has Fallen at -17.95%
  • PRE-TAX PROFIT(Q) At VND -2,719.45 MM has Fallen at -238.56%
  • NET PROFIT(Q) At VND -3,070.83 MM has Fallen at -365.29%
2

Risky -

3

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Medical Specialties

stock-summary
Market cap

VND Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.09

stock-summary
Return on Equity

-3.57%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
39,522 Million
(Quarterly Results - Dec 2025)
Net Profit:
-3,294 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.0%
0%
-10.0%
6 Months
-10.0%
0%
-10.0%
1 Year
-10.0%
0%
-10.0%
2 Years
-48.57%
0%
-48.57%
3 Years
-53.85%
0%
-53.85%
4 Years
-82.4%
0%
-82.4%
5 Years
-85.05%
0%
-85.05%

American Vietnamese Biotech, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-3.99%
EBIT Growth (5y)
-182.66%
EBIT to Interest (avg)
2.61
Debt to EBITDA (avg)
1.50
Net Debt to Equity (avg)
0.09
Sales to Capital Employed (avg)
0.15
Tax Ratio
58.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.68%
ROE (avg)
4.40%

Valuation key factors

Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
9.58
EV to EBITDA
3.44
EV to Capital Employed
0.08
EV to Sales
0.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.86%
ROE (Latest)
-0.11%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 211.42% vs -66.86% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 69.68% vs 71.14% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "39,522.10",
          "val2": "12,690.80",
          "chgp": "211.42%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,063.60",
          "val2": "8,686.30",
          "chgp": "-76.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "4,983.00",
          "val2": "4,480.40",
          "chgp": "11.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "197.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3,293.60",
          "val2": "-10,861.40",
          "chgp": "69.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "52.20%",
          "val2": "8.30%",
          "chgp": "4.39%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -50.36% vs 57.88% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -317.17% vs -221.74% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "154,066.60",
          "val2": "310,354.60",
          "chgp": "-50.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5,327.00",
          "val2": "19,689.90",
          "chgp": "-72.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "18,655.30",
          "val2": "19,650.50",
          "chgp": "-5.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54,503.70",
          "val2": "-13,065.20",
          "chgp": "-317.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-179.00%",
          "val2": "-13.90%",
          "chgp": "-16.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
39,522.10
12,690.80
211.42%
Operating Profit (PBDIT) excl Other Income
2,063.60
8,686.30
-76.24%
Interest
4,983.00
4,480.40
11.22%
Exceptional Items
197.10
0.00
Consolidate Net Profit
-3,293.60
-10,861.40
69.68%
Operating Profit Margin (Excl OI)
52.20%
8.30%
4.39%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 211.42% vs -66.86% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 69.68% vs 71.14% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
154,066.60
310,354.60
-50.36%
Operating Profit (PBDIT) excl Other Income
5,327.00
19,689.90
-72.95%
Interest
18,655.30
19,650.50
-5.06%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-54,503.70
-13,065.20
-317.17%
Operating Profit Margin (Excl OI)
-179.00%
-13.90%
-16.51%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -50.36% vs 57.88% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -317.17% vs -221.74% in Dec 2024

stock-summaryCompany CV
About American Vietnamese Biotech, Inc. stock-summary
stock-summary
American Vietnamese Biotech, Inc.
Medical Specialties
American Vietnamese Biotech Incorporation (AmviBiotech) is a Vietnam-based company engaged in the pharmaceutical industry. The Company is involved in the manufacture of medicines, vaccines and biological products. It is also involved in the manufacture of rapid diagnostic tests and ELISA kits, as well as the trading of other medical equipment and tools. In addition, the Company is active in the manufacture of cosmetic, soaps, detergents and other polishing and cleaning products. Its other activities include real estate trading, financial investment and the manufacture of plastic products. As of December 31, 2012, the Company had one wholly owned subsidiary named American - Vietnamese Biology Company Limited.
Company Coordinates stock-summary
Company Details
So 1251 QL 14, thi xa Dong Xoai , HO CHI MINH None : None
stock-summary
Tel: 84 651 3889034
stock-summary
Registrar Details